Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100890 | 0.92 | PTPN1 (0.48) | PTPN1S1PR1FFAR1 | |
| SCHEMBL28805778 | 0.91 | PTPN1 (0.47) | PTPN1S1PR1HDAC1HDAC2HDAC8 | |
| SCHEMBL9100995 | 0.91 | PTPN1 (0.47) | PTPN1S1PR1HDAC1HDAC8FFAR1 | |
| SCHEMBL9106624 | 0.86 | S1PR1 (0.55) | PTPN1S1PR1HDAC1HDAC2HDAC8 | |
| SCHEMBL9103709 | 0.85 | S1PR1 (0.55) | PTPN1S1PR1FFAR1 | |
| SCHEMBL9104686 | 0.85 | PTPN1 (0.46) | PTPN1S1PR1HDAC1HDAC8FFAR1 | |
| SCHEMBL27938890 | 0.84 | PTPN1 (0.49) | PTPN1S1PR1HDAC1HDAC8FFAR1 | |
| SCHEMBL27938780 | 0.84 | PTPN1 (0.48) | PTPN1S1PR1HDAC1HDAC2HDAC8 | |
| SCHEMBL15667449 | 0.83 | PTPN1 (0.47) | PTPN1S1PR1 | |
| SCHEMBL9912337 | 0.81 | PTPN1 (0.44) | PTPN1S1PR1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846728-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20130303577-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. | 2013-11-14 | — | — | US | claimed |
| EP-2646021-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P)RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| US-8497254-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-07-30 | — | — | US | claimed |
| WO-2012074730-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P)RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142639-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | claimed |
| EP-2646021-B1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P)RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8846728-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846728-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846728-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130303577-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130303577-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130303577-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8497254-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497254-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497254-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2012074730-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P)RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142639-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142639-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142639-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142639-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | PTPN1 1043/4885S1PR1 2/4885HDAC1 1239/4885 |
| US-20130303577-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | PTPN1 1043/4885S1PR1 2/4885HDAC1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.